Gastric Cancer - Epidemiology, Modifiable and Non-modifiable Risk Factors, Challenges and Opportunities: An Updated Review

Cancer Treatment and Research Communications, Journal Year: 2024, Volume and Issue: 41, P. 100845 - 100845

Published: Jan. 1, 2024

Language: Английский

---

Plasmonic Nanoparticles: Enhancing Early Breast Cancer Detection Through Biosensors

Plasmonics, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Language: Английский

---

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

---

From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 320 - 320

Published: Jan. 20, 2025

Endometrial cancer (EC), a prevalent gynecological malignancy, presents significant challenges due to its genetic complexity and heterogeneity. The genomic landscape of EC is underpinned by alterations, such as mutations in PTEN, PIK3CA, ARID1A, chromosomal abnormalities. identification molecular subtypes—POLE ultramutated, microsatellite instability (MSI), copy number low, high—illustrates the diverse profiles within underscores need for subtype-specific therapeutic strategies. integration multi-omics technologies single-cell genomics spatial transcriptomics has revolutionized our understanding approach studying offers holistic perspective that enhances ability identify novel biomarkers targets. translation these findings into personalized medicine precision oncology increasingly feasible clinical practice. Targeted therapies PI3K/AKT/mTOR inhibitors have demonstrated potential improved treatment efficacy tailored specific alterations. Despite advancements, persist terms variability patient responses, data workflows, ethical considerations. This review explores underpinnings EC, from genes It highlights ongoing multidisciplinary research collaboration address complexities improve diagnosis, treatment, outcomes.

Language: Английский

---

Immuno-PCR: A high-sensitivity approach for biomarker analysis

Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120289 - 120289

Published: April 1, 2025

Language: Английский

---

Efficiency of electrochemical immuno- vs. apta(geno)sensors for multiple cancer biomarkers detection

Talanta, Journal Year: 2024, Volume and Issue: 281, P. 126870 - 126870

Published: Sept. 17, 2024

Language: Английский

---

CRISPR/Cas12a Corona Nanomachine for Detecting Circulating Tumor Nucleic Acids in Serum

Analytical Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 5, 2024

Circulating tumor nucleic acids (CTNAs), which consist of cell-free DNA or RNA released from cells, are utilized as potential biomarkers for diagnosing and managing prognosis. There is a significant demand developing highly sensitive reliable assay CTNAs detection. In this study, we engineered CRISPR/Cas12a corona nanomachine capable detecting circulating in serum. This consists protein shell incorporating Cas12a/crRNA ribonucleoprotein complexes scaffold AuNP core decorated with substrate ssDNA strands. The protective CRISPR shields the acid degradation by nuclease DNase/RNase, thereby enhancing stability biological fluids, even tolerating up to undiluted human serum FBS. Upon encountering target CTNAs, activated through sequence-specific hybridization between crRNA CTNAs. Subsequently, autonomously cleaves collateral substrates on AuNPs, releasing fluorophore-labeled fragment generating an increasing fluorescent signal. was successfully employed detect various including (ct)DNA/RNA (EGFR L858R) microRNA-21, achieving limit detection 0.14 pM ctDNA 1.0 RNA. enables simultaneous both complex samples, offering promising tool early diagnosis.

Language: Английский

---

Liquid biopsy: an emerging field with new opportunities for cancer diagnosis and prognosis

Asia-Pacific Journal of Oncology, Journal Year: 2025, Volume and Issue: unknown, P. 9 - 17

Published: Jan. 14, 2025

Cancer grades among the deadliest diseases, globally causing death of a over million people each year. Early diagnosis has been considered ideal for efficient treatment as during later stages chances become limited. However, gold standard tissue biopsy various limitation instance, late-stage and its intrusive operation making it unfit repeated sampling. Scientists are passionately looking new technologies techniques cancer prognosis. Liquid emerged diagnostic prognostic tool cancer, that relies on body fluids to identify biomarkers cancer. It offers advantages like non-invasive operation, timely detection, amenable sampling, covers tumor heterogeneity. Wide attention garnered by liquid is undergoing rapid progress in list target biomarkers. The most common circulating cells, DNA, exosomes, educated platelets, non-coding RNAs (miRNA, lncRNA etc.). Each these have unique advantages, indeed technology future with clinical utility. In this article, we tried provide thorough introduction markers, highlighted deployed biopsy, briefly overview their implications indispensable entities diverse types Moreover, discussed prospects revolutionary realm treatment.

Language: Английский

---

Predicting Early Death in Head and Neck Cancer—A Pilot Study

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 302 - 302

Published: Jan. 17, 2025

Background: The aim of this study was to evaluate biomarkers and biological characteristics tumor biopsies from patients with head neck cancer (HNC) assess the risk early death. Furthermore, we analyzed whether any combination markers could be used for prognostication death within six months after diagnosis. Materials Methods: Patients diagnosed HNC, receiving curative treatment decision at a multidisciplinary board meeting, who died diagnosis were included in study. Nine identified matched according site stage seventeen survived least two years. Results: expression compared between early-death survivors. There significantly higher Ki-67 than those surviving years, mean difference 21% (p = 0.038). A significant cytoplasmic survivin noted where had increased survivors 0.021). intensity staining differed groups 0.006). Conclusions: results pilot indicate that Ki67 potential prognostic HNC possibly panel value making.

Language: Английский

---

A Dual Nano-Signal Probe-Based Electrochemical Immunosensor for the Simultaneous Detection of Two Biomarkers in Gastric Cancer

Biosensors, Journal Year: 2025, Volume and Issue: 15(2), P. 80 - 80

Published: Jan. 31, 2025

Detecting multiple tumor markers is of great importance. It helps in early cancer detection, accurate diagnosis, and monitoring treatment. In this work, gold nanoparticles–toluidine blue–graphene oxide (AuNPs-TB–GO) nanoparticles–carboxyl ferrocene–tungsten disulfide (AuNPs–FMC–WS2) nanocomposites were prepared for labeling Carcinoembryonic antigen (CEA) antibody Carbohydrate 72–4 (CA72-4) antibody, respectively, used as two kinds probes with different electrochemical signals. With the excellent magnetic performance biotin immune beads (IMBs), biofunctional IMBs firmly deposited on glassy carbon electrode (MGCE) surface by applying a constant field, then CEA CA72-4 immobilized avidin–biotin conjugation. The assay was based change detection peak current. Under optimum experimental conditions, linear range two-component immunosensor from 0.01 to 120 ng/mL, low limit 0.003 0.05 35 U/mL, 0.016 U/mL. results showed that proposed enabled simultaneous exhibited good reproducibility, high selectivity, sensitivity. particular, multiplexed immunoassay approach does not require sophisticated fabrication well-suited high-throughput biosensing application other areas.

Language: Английский

---